Research Options:

Week of Expected Pricing Pending
Company Name Ikaria
Proposed Ticker IKAR
CUSIP 45173V107
Business Description A fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the significant unmet medical needs of critically ill patients.
Lead Underwriter Goldman, Sachs/ Morgan Stanley
Co-Managers Credit Suisse/ Lazard Capital Markets/ Cowen/ Wedbush PacGrow Life Sciences/ Soleil Securities/ SunTrust Robinson Humphrey
Initial Shares 10000000
Revised Initial Shares N/A
Initial Price $15.00-$17.00
Revised Price N/A
Final Price N/A
Final Ticker N/A

 

 

   
  © 2024 ICE Data Services. All rights reserved.